Tsuyoshi Horikawa

421 total citations
12 papers, 312 citations indexed

About

Tsuyoshi Horikawa is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Tsuyoshi Horikawa has authored 12 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Tsuyoshi Horikawa's work include Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (7 papers) and Blood Pressure and Hypertension Studies (4 papers). Tsuyoshi Horikawa is often cited by papers focused on Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (7 papers) and Blood Pressure and Hypertension Studies (4 papers). Tsuyoshi Horikawa collaborates with scholars based in Japan. Tsuyoshi Horikawa's co-authors include Takashi Nomiyama, Toshihiko Yanase, Yuriko Hamaguchi, Takako Kawanami, Makito Tanabe, Daiji Kawanami, Ryoko Motonaga, Taku Obara, Akinori Iwasaki and Takayoshi Ohkubo and has published in prestigious journals such as Endocrinology, Diabetes Research and Clinical Practice and Heliyon.

In The Last Decade

Tsuyoshi Horikawa

12 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tsuyoshi Horikawa Japan 10 152 151 96 82 66 12 312
Takafumi Majima Japan 10 104 0.7× 93 0.6× 60 0.6× 103 1.3× 73 1.1× 16 348
Xufei Yang China 8 130 0.9× 176 1.2× 90 0.9× 64 0.8× 34 0.5× 11 368
Kenichi Tsujii Japan 7 90 0.6× 113 0.7× 73 0.8× 198 2.4× 91 1.4× 12 362
A Aldibbiat United Kingdom 11 145 1.0× 112 0.7× 57 0.6× 125 1.5× 32 0.5× 14 388
Mamiko Tsugawa Japan 11 215 1.4× 77 0.5× 56 0.6× 69 0.8× 28 0.4× 21 324
Maria E. Rämet Finland 6 166 1.1× 76 0.5× 105 1.1× 138 1.7× 15 0.2× 6 373
Sinan Tanyolaç Türkiye 7 100 0.7× 97 0.6× 33 0.3× 45 0.5× 36 0.5× 11 264
L. Redaelli Italy 7 135 0.9× 52 0.3× 107 1.1× 68 0.8× 19 0.3× 22 362
Kalie L. Tommerdahl United States 13 140 0.9× 69 0.5× 24 0.3× 62 0.8× 26 0.4× 35 331

Countries citing papers authored by Tsuyoshi Horikawa

Since Specialization
Citations

This map shows the geographic impact of Tsuyoshi Horikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsuyoshi Horikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsuyoshi Horikawa more than expected).

Fields of papers citing papers by Tsuyoshi Horikawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsuyoshi Horikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsuyoshi Horikawa. The network helps show where Tsuyoshi Horikawa may publish in the future.

Co-authorship network of co-authors of Tsuyoshi Horikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Tsuyoshi Horikawa. A scholar is included among the top collaborators of Tsuyoshi Horikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsuyoshi Horikawa. Tsuyoshi Horikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Yamashita, Shin-ichi, Takashi Nomiyama, Takako Kawanami, et al.. (2021). Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetology International. 12(4). 389–398. 32 indexed citations
2.
Tanaka, Yuki, Takako Kawanami, Yuriko Hamaguchi, et al.. (2021). Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetology International. 13(3). 480–492. 9 indexed citations
3.
4.
Horikawa, Tsuyoshi, Takako Kawanami, Yuriko Hamaguchi, et al.. (2020). Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet. Heliyon. 6(11). e05431–e05431. 10 indexed citations
5.
Shigeoka, Toru, Takashi Nomiyama, Takako Kawanami, et al.. (2020). Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression. Journal of Diabetes Investigation. 11(5). 1137–1149. 24 indexed citations
6.
Nomiyama, Takashi, Tomohiro Numata, Takako Kawanami, et al.. (2019). SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocrine Journal. 67(1). 99–106. 63 indexed citations
7.
8.
Nomiyama, Takashi, Takako Kawanami, Yoko Tsutsumi, et al.. (2017). Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation. Endocrinology. 158(12). 4218–4232. 62 indexed citations
9.
Horikawa, Tsuyoshi, Taku Obara, Takayoshi Ohkubo, et al.. (2008). Difference between Home and Office Blood Pressures among Treated Hypertensive Patients from the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertension Research. 31(6). 1115–1123. 13 indexed citations
10.
Obara, Taku, Takayoshi Ohkubo, Hirohito Metoki, et al.. (2006). Current Usage of Diuretics among Hypertensive Patients in Japan: The Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertension Research. 29(11). 857–863. 16 indexed citations
11.
Obara, Taku, Takayoshi Ohkubo, Masahiro Kikuya, et al.. (2006). The current status of home and office blood pressure control among hypertensive patients with diabetes mellitus: The Japan Home Versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Diabetes Research and Clinical Practice. 73(3). 276–283. 18 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takafumi Majima Breakdown of academic impact, for papers by Xufei Yang Breakdown of academic impact, for papers by Kenichi Tsujii Breakdown of academic impact, for papers by A Aldibbiat Breakdown of academic impact, for papers by Mamiko Tsugawa Breakdown of academic impact, for papers by Maria E. Rämet Breakdown of academic impact, for papers by Sinan Tanyolaç Breakdown of academic impact, for papers by L. Redaelli Breakdown of academic impact, for papers by Kalie L. Tommerdahl
Rankless by CCL
2026